decades and have imposed dramatic success on the history of modern medicines 3 . Inhaled corticosteroids (ICSs), as an asthma controller, and short-acting β-agonists (SABAs), as a symptom reliever, are widely used for asthma management. However, these two inhaler medications have adverse effects which we should pay attention to.
In the real world, asthma patients tend to intermittently use ICS and more likely to be dependent on SABA since many patients want to immediate relief of their symptoms. Consequently, a dilemma exists regarding the underuse of ICSs but the overuse of SABAs has been observed. agement of asthma, one of the leading respiratory diseases. Even in the early 1990s, patients with asthma exacerbations were more frequent in the emergency room. Some of them had to undergo airway intubation and mechanical ventilation. However, as the use of asthma controller medications in the early 2000s began to increase, the number of asthmatic patients who visited the emergency room decreased sharply, and the number of hospitalized asthmatic patients decreased even more, making it difficult to see asthmatic patients in the hospital wards.
Efficacy of ICSs and recommendations by the guidelines for asthma management
Asthma controller medications have proven to be efficacious in many aspects through large-scale observational studies and randomized clinical trials. ICSs, for example, have been shown to reduce asthma mortality, reduce asthma exacerbations, and improve asthma symptoms and lung function 4 . Due to the proven strong efficacy, ICSs are recommended as the most important asthma controller medications in both international and domestic asthma guidelines 5, 6 .
Adverse effects of ICSs
ICSs have been reported to have few adverse effects, unlike oral or injectable corticosteroids, but to increase the risk of adverse effects when used in high doses. For example, the risk for respiratory tract infections such as pneumonia, pulmonary tuberculosis, and non-tuberculous mycobacterial infections has been reported to increase [7] [8] [9] . It has also been reported that the risk of cataract increases and bone density slightly decreases [10] [11] [12] .
ICSs dilemma at the step 1 of mild asthma management
Because the ICSs have adverse effects, it is recommended in the guidelines that if asthma is controlled, the treatment level should be lowered to reduce the dose of ICSs and to use the minimum maintenance dose. Furthermore, the guidelines state that asthma controller medications may not be used for the patient at the step 1 of mild asthma management. This strategy is advantageous in reducing the adverse effects of ICSs, but it also has the disadvantage in that the deterioration of asthma may not be prevented.
In particular, given the insufficient use of asthma controller medications, which is true in current practices, the recommendation of only SABAs without ICSs may not be appropriate.
Success and Dilemma of SABAs

Rapid symptom improvement by SABAs
SABAs (e.g., salbutamol in metered dose inhaler [MDI]) are not asthma controllers, but they have a rapid symptom-relieving effect and so have widely been used by asthma patients. For example, the salbutamol MDI, which is widely used in Korea, starts the action of bronchodilator is about 4 minutes, and reaches the peak at about 80 minutes 13 . Due to the rapid action of SABAs, it is advisable to use them when needed.
However, because SABAs do not have any anti-inflammatory effect but only have bronchodilation, they cannot prevent the asthma worsening and should be used as a temporary symptom reliever. Therefore, the asthma guidelines recommend that SABAs be used temporarily only when the asthma symptoms are worse 5 . Although a SABA has the effect of promptly improving symptoms, it might cause asthma death, a rare but serious adverse effect. The adverse effect of asthma death problems was raised from the 1980s when the use of SABAs increased, and it has been repeatedly observed through large-scale observational studies 14, 15 .
Dilemma of SABAs at the step 1 of the asthma management guidelines
At the step 1 of the asthma management guidelines, asthma patients with intermittent symptom may be treated only with a SABA 5 . However, the SABAs should not be encouraged to use only because the SABAs have no anti-inflammatory effect but have a rare but cardiac death 16 . Moreover, even mild asthma may change to moderate or severe during the disease course. Asthma is well known to be characterized by the variation of symptoms and also disease course. So the dilemma of SABAs at the step 1 of the asthma management should be solved.
Strategies of Solutions for Asthma
Treatment Dilemmas
Strategy of solution for the ICSs dilemma
A solution strategy for the ICSs dilemma may be suggested with defining asthma patients who need a controller persistently. ICSs are a mainstay medication for asthma control but have some adverse effects as mentioned in this article. Considering the balance between the necessity and adverse effects of ICSs, persistent use of low dose ICS should be suggested the asthma patients who need a controller persistently. We may name the patient, a 'persistent controller user' . For the Tuberc Respir Dis 2019;82: [190] [191] [192] [193] www.e-trd.org persistent controller user, a controller(s) should be used for a lifetime, because the necessity of controller (e.g., ICS) outweighs the adverse effects Then, who are the persistent controller users? They may be the two groups of asthma patients ( Table 1 and strategy 1 of  Table 2 ). One is the group of patients at risk for exacerbation and the other is the group of patients who have failed the trial of a controller discontinuation.
Conversely, if an asthma patient is not the "persistent controller user," he or she will be able to try to discontinue the asthma controller. Even when discontinued, the asthma controller (e.g., a ICS) should be restarted whenever the asthma state is uncontrolled.
Strategy of solution for the SABAs dilemma
The SABAs dilemma may be solved by using a combined inhalation of ICS and rapid onset long acting β-agonist (LABA) (strategy 2 of Table 2 ). Asthma is a disease with its variation of course, good and bad, so it sometimes is necessary to use bronchodilator immediately when symptoms develop. However, as described above, the single use of β agonist cannot be expected to have an anti-inflammatory effect, so there is a risk of asthma exacerbation and rarely asthma death. Therefore, O'Byrne et al. 17 recently proposed to use a combined inhalation of ICS and rapid onset LABA (e.g., formoterol) at the earlier steps of asthma treatment. Formoterol is an example of the rapid onset LABA, which is known to start its effect at 5 minutes and peak at about 2 hours due to its short onset time 13 . The main advantage of the combined ICS and rapid onset LABA together is that it can prevent the risk of asthma death albeit rare. In addition, we can use the combination of ICS and rapid onset LABA in a single device with convenience compared to using the two inhalers separately. So from the step 1 Table 1 Step 2 Low-dose ICSs
Step 3 Low-dose ICSs/LABAs Same as the current guideline (see the column of Current guideline)
Step 4
Medium/high ICS/ LABA SABA as needed or low-dose ICSs/ rapid-onset LABAs §
Step 5 The strategy might be applied from the step 1 to some cases of the step 2 in the Asthma Guideline. § Formoterol is an example. ICS: inhaled corticosteroids; SABA: short-acting β2 agonist; LABA: long acting β2 agonist. www.e-trd.org to some cases of the step 2, patients may by themselves adjust the use of low dose ICS/rapid onset LABA from intermittent to regular. This patient-adjusted symptom-driven intermittent to regular treatment with low dose ICS/rapid onset LABA would be one strategy of solution to solve the dilemma 18 .
Conclusion
ICSs and SABAs, which are key medications for asthma treatment, are widely used as an asthma controller and a symptom reliever, respectively. Because of adverse effects, there is a dilemma that is difficult to recommend for a persistent lifetime use of ICS for mild asthma patients. In this article, we suggested that the ICSs dilemma should be solved by defining a 'persistent controller user' who should use the ICS persistently and that the SABAs dilemma might be solved by using patient-adjusted symptom-driven intermittent to regular treatment with low dose ICS/rapid onset LABA to mild asthma patients at the step 1 and some patients of the step 2.
Both of these two strategies could avoid the risky treatment of a SABA alone without an ICS and could reduce the dose of ICS with the maintenance of asthma control.
